China’s 2026 National Reimbursement Drug List Negotiations Set for Sept 5

The fixed date signals a predictable regulatory cadence for drug pricing in China, which matters for market planning across pharma and biotech. The parallel price consultations for the commercial insurance catalog suggest a broadening of reimbursement channels beyond the state scheme. With pre-communication done, the focus shifts to how aggressive the price cuts will be, especially for innovative drugs. Whether the four-to-five-day window yields quicker or more drawn-out concessions is the immediate variable to watch.